TGFB1 and neoplasm: In the context of an ‘immune‐excluded’ phenotype, TGF‐β promoted activation of CAFs, which serve as a barrier to T‐cell infiltration of the tumor parenchyma, that has been shown to limit the efficacy of anti‐PD‐L1 therapy in bladder cancer [17].